Navigation Links
New and Interesting PROSTVAC(TM) Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer
Date:9/22/2009

KVISTGAARD, Denmark, September 22 /PRNewswire-FirstCall/ -- Bavarian Nordic A/S (OMX: BAVA) yesterday presented further detailed PROSTVAC(TM) data at the European Cancer Organisation (ECCO), ECCO 15 - 34th ESMO Congress in Berlin, Germany.

Further data from a Phase II double-blind, prospective randomized placebo-controlled study of 125 patients with metastatic prostate cancer was presented by Dr. Wayne Godfrey, Senior Medical Director, BN ImmunoTherapeutics.

The headline data as previously reported showed that patients in the PROSTVAC(TM) group had a significantly longer median overall survival by 8.5 months compared to the control group. The hazard ratio estimate for overall survival from the study is 0.56 (95% CI 0.37-0.85). The statistical significance in the final data set is (p=0.006). PROSTVAC(TM) also demonstrated a very favourable safety and tolerability profile.

A new statistical analysis of the data set showed that patients receiving PROSTVAC(TM) benefitted from the treatment regardless of their general condition or their median predicted survival, determined by the Halabi score. Similarly, when grouped by a number of relevant parameters, e.g. PSA level, PROSTVAC(TM) patients benefitted from treatment as compared to the control group. This data indicates that PROSTVAC(TM) is universally applicable to a wide range of prostate cancer patients. This confirms PROSTVAC(TM)'s potential to address a significant medical need and market opportunity. Furthermore, it will be useful in further defining the patient population for the pivotal phase III program.

An abstract from Dr. Godfrey's presentation is now available online at http://ex2.excerptamedica.com/CIW-09ecco/

Abstract no. O-7002.

Title: "Further analysis of a Phase II randomized controlled trial (
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)
2. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
3. New Independent Research Study Indicates That Cylexs ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection
4. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
5. Principle of Recursive Genome Function Supersedes Dogmas; By Andras Pellionisz, Online Ahead of Print; (Scientific Visionary Vindicated)
6. U.S. Clinicians Indicate a Strong Need for New Tools to Combat Sepsis
7. PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
8. Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
9. New study indicates smallpox vaccination effective for decades
10. New study indicates smallpox vaccination effective for decades
11. Surveyed Experts Indicate That Byetta LAR and Victoza Have Advantages Over Actos in the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... ANGELES , May 26, 2015 Pharmaco-Kinesis ... Board (NOCAB) recently convened at Shutters on the Beach ... review the development status of the Company,s innovative Metronomic ... designed to locally deliver chemotherapy over time to a ... dose delivery capacity and biofeedback system in real-time.  ...
(Date:5/26/2015)... 26, 2015 Mr. Kevin Xu , President ... Barack Obama and President Bill Clinton ... loss of Dr. Rongxiang Xu , Kevin,s father. ... ahead of his time, Dr. Xu,s commitment to the advancement ... legacy that will not be forgotten. As a renowned life ...
(Date:5/26/2015)... May 26, 2015 /PRNewswire/ - Fluorinov Pharma (Fluorinov), a ... Luke M. Beshar to its Board of Directors. ... pharmaceutical industry expertise as Fluorinov accelerates its clinical development ... team, it is a pleasure to welcome Luke to ... impact on the strategy, financial strength and success of ...
(Date:5/26/2015)... PRC Clinical, the Clinical Trial ... Regenerative Medicine (ARM). The ARM counts more than ... commercialization of transformational treatments and cures for patients ... CRO focused in Clinical Trial Management, has developed ... research working with sponsors in the United States ...
Breaking Biology Technology:Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Dr. Rongxiang Xu, Beyond A Legend 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 3PRC Clinical Joins 200+ Member Organizations in The Alliance for Regenerative Medicine (ARM) 2PRC Clinical Joins 200+ Member Organizations in The Alliance for Regenerative Medicine (ARM) 3
... ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, ... Institute of Allergy and Infectious Diseases (NIAID) at ... USA. The research collaboration involves formulating NIAID antigens ... potential vaccines for HIV and malaria. , "NIAID ...
... VIEW, California, February 25 BN,ImmunoTherapeutics, Inc. announced ... the vaccine was licensed from the National Institutes ... once again confirms the,excellent safety and efficacy results ... Cancers Symposium (GU) on February 26-28, 2009 in,Orlando, ...
... 25 Cerimon Pharmaceuticals, Inc., announced today ... once-daily topical diclofenac sodium patch Phase III program. ... III clinical studies with Cerimon,s diclofenac patch. The ... diclofenac patch compared to placebo for the treatment of ...
Cached Biology Technology:ImmunoVaccine Technologies Signs Agreement with National Institutes of Health to Explore Vaccines for HIV and Malaria 2BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM) 2BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM) 3Cerimon Pharmaceuticals Initiates Phase III Clinical Studies to Evaluate Its Topical Diclofenac Sodium Patch for Mild-to-Moderate Pain 2
(Date:5/25/2015)... May 25, 2015  Australia,s market for wearable technologies ... 2014 saw the advent of several trials and prototypes. ... 2015 is expected to ignite interest in wearables as ... Australia . This in turn will spur ... drive new partnerships amongst vendors and distributors. ...
(Date:5/21/2015)... DALLAS , May 21, 2015 ... report, "Thermal Imaging Market by Solutions (Hardware, Software, Services), ... Veterinary, Automotive & others), by End-Users (Military & ... published by MarketsandMarkets, Thermal Imaging Market is expected ... $9998.9 Million by 2020, at a Compound Annual ...
(Date:5/20/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... subsidiary, 3D-ID LLC, a company engaged in biometric identification ... biometrics technology portion of the recently awarded TIES (Technical ... of the Army. 3D-ID LLC has a ... law enforcement and security agencies. Gino ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... WASHINGTON -- Recipients of the 10th annual Communication Awards ... National Academy of Engineering, and Institute of Medicine. ... part of the Keck Futures Initiative, these prestigious awards ... recognize excellence in reporting and communicating science, engineering, and ...
... Ghrelin is a hormone released by the lining of the ... help combat obesity -- in fact, a vaccine that lowers ... as a treatment for obesity. However, many people eat ... increase stress, its effectiveness as a treatment for obesity may ...
... RIVERSIDE, Calif. -- Turfgrass and landscape professionals will have the ... and management on Thursday, Sept. 13, 2012, at the University ... a.m. and ending at 2:30 p.m., will be held at ... King Blvd., Riverside. Parking will be available in ...
Cached Biology News:Daniel Kahneman's 'Thinking, Fast and Slow' wins best book award from academies 2Low ghrelin -- reducing appetite at the cost of increased stress? 2Turfgrass and Landscape Research Field Day to be held in California, Sept. 13 2
... for microRNA expression profiling ,miRCURY ... Locked Nucleic Acid (LNA) technology to provide ... short microRNA (miRNA) targets. miRCURY LNA Arrays ... RNA (no need for microRNA enrichment) labeled ...
... slightly cloudy liquid. Yellow, oily, bacterial ... each containing 10 ml of Freund's ... proportions by weight: 85% Drakeol 5NF, ... and 0.1% Mycobacterium butyricum ...
With sodium bicarbonate. Sterile, Cell culture tested...
For removal of the zona pellucida. Sterile, Mouse Embryo tested...
Biology Products: